What is the latest TB management guidelines in India
Reading File
Searching the Web
India TB management guidelines 2024 2025 NTEP RNTCP latest
Searching PubMed
tuberculosis management guidelines India NTEP
Finding Sources
Reading Web Page
https://link.springer.com/article/10.1186/s12982-026-01451-x
Finding Sources
Searching the Web
NTEP India TB guidelines 2024 drug sensitive drug resistant treatment regimen BPaL BPaLM
Finding Sources
Reading Web Page
https://www.droracle.ai/articles/957437/what-are-the-current…
Finding Sources
Reading File
Finding Sources
Finding Sources
Reading File
Reading File
Reading File
Reading File
I now have comprehensive information from multiple sources. Let me compile the full answer on India's latest TB management guidelines.
Latest TB Management Guidelines in India (NTEP 2024-2026)
India manages TB through the National Tuberculosis Elimination Programme (NTEP), formerly RNTCP, under the Central TB Division (CTD) of the Ministry of Health & Family Welfare. The overarching goal is TB elimination by 2025 - five years ahead of the global 2030 target. As of 2026, India has achieved a 21% reduction in new TB cases and 28% drop in deaths since 2015 (WHO Global TB Report 2025).
Programme Framework: Detect - Treat - Prevent - Build
The National Strategic Plan (NSP) rests on four pillars:
- Detect - Early diagnosis via high-quality testing and community outreach
- Treat - Prompt, quality-assured treatment for both DS-TB and DR-TB
- Prevent - TB Preventive Therapy (TPT) for high-risk groups
- Build - Health system strengthening and multisectoral engagement
A. Diagnosis
1. Presumptive TB: Any patient with symptoms/signs suggestive of TB (cough >2 weeks, fever, night sweats, weight loss).
2. Bacteriological Confirmation Tools (NTEP-endorsed):
- Sputum smear microscopy - initial screen
- CBNAAT (Xpert MTB/RIF / TrueNat) - mandatory for all new cases; simultaneously detects TB and rifampicin resistance
- Line Probe Assay (LPA) - first-line and second-line; detects resistance to isoniazid, rifampicin, fluoroquinolones, and injectables
- Liquid culture (MGIT) - for complex cases and DST
- AI-assisted chest X-ray screening - deployed under TB Mukt Bharat Abhiyan for mass screening
- AI cough analysis - India is pioneering AI-driven cough screening for active case finding
3. Case Classification:
- Bacteriologically confirmed vs Clinically diagnosed
- Further classified by: anatomical site (pulmonary/extrapulmonary), treatment history (new/previously treated), drug resistance pattern, and HIV status
B. Drug-Sensitive TB (DS-TB) Treatment
Under NTEP, all treatment is daily fixed-dose combination (FDC), weight-band based, replacing the earlier intermittent DOTS regimen.
| Category | Regimen | Duration |
|---|---|---|
| New cases (all forms) | 2HRZE / 4HR | 6 months |
| Previously treated | 2HRZES / 1HRZE / 5HRE (or as per DST) | 8 months |
| TB Meningitis / Bone-Joint / Spinal TB | 2HRZE / 10HR | 12 months |
- H = Isoniazid, R = Rifampicin, Z = Pyrazinamide, E = Ethambutol, S = Streptomycin
- All patients are registered on Ni-Kshay (digital case management system)
- Nikshay Poshan Yojana (NPY): Rs. 1,000/month nutritional support for every TB patient throughout treatment duration
- TB Aarogya Saathi app - mobile app linked to Ni-Kshay for treatment adherence monitoring
C. Drug-Resistant TB (DR-TB) - Key Updates 2024
New BPaLM Regimen (Landmark 2024 Change)
The most significant recent update: The Union Health Ministry approved the BPaLM regimen in 2024 for MDR/RR-TB:
| Drug | Full Name |
|---|---|
| B | Bedaquiline |
| Pa | Pretomanid |
| L | Linezolid |
| M | Moxifloxacin (optional, adds to BPaL) |
- Reduces MDR-TB treatment from ~20 months to just 6 months
- More effective and safer than previous longer regimens
- As of March 2026, over 15,000 MDR/RR-TB patients have been initiated on this regimen across India
- Eligible for adults and adolescents ≥14 years
Older DR-TB regimens (still used where BPaLM not applicable):
- Shorter oral regimen (9-12 months): BedaquilineLinezolid-based (for pre-XDR)
- Longer regimen (18-20 months): Individualized based on DST results
DR-TB Categorization (NTEP):
- RR-TB / MDR-TB - Rifampicin-resistant or resistant to Rifampicin + Isoniazid
- Pre-XDR-TB - MDR/RR-TB + resistance to any fluoroquinolone
- XDR-TB - MDR/RR-TB + resistance to fluoroquinolone + bedaquiline or linezolid
All new TB patients are tested for rifampicin resistance by CBNAAT, and for H/R resistance by LPA, before treatment initiation.
D. TB Preventive Therapy (TPT)
For high-risk groups (household contacts of TB patients, PLHIV, immunosuppressed patients on biologics):
- 6H: Isoniazid for 6 months
- 3HP: Isoniazid + Rifapentine weekly for 3 months (preferred where available)
- Screening of all household contacts, especially children <5 years and PLHIV
E. Special Populations
| Population | Key Guidance |
|---|---|
| HIV-TB co-infection | Start ART within 2 weeks of TB treatment (irrespective of CD4); use same DS-TB regimen; avoid rifampicin-PI interactions |
| Children | Weight-band FDC dosing; dispersible formulations preferred; modified eligibility for BPaLM regimen in adolescents ≥14 yrs |
| Pregnant women | Treat with standard DS-TB regimen; avoid streptomycin; individualized DR-TB management |
| Diabetes | Active screening; closer monitoring; longer treatment consideration |
| Extrapulmonary TB | CNS/bone/joint TB: 12-month regimen; separate new extrapulmonary TB guidelines under development (NTI workshop, 2024) |
F. Programme Infrastructure
- DR-TB Centres (DR-TBCs): Established at nodal (1 per 10 million population) and district level across India; 147+ centres operational
- Ni-Kshay platform: Mandatory case notification for all TB cases (public and private sector)
- Private sector engagement: Mandatory notification; incentives for private providers (Rs. 500 notification + Rs. 500 outcome reporting)
- TB Mukt Bharat Abhiyan (Dec 2024 onward): Mass screening drive - over 20 crore people screened, 28 lakh TB patients diagnosed (9 lakh asymptomatic)
- Treatment success rate: 90% (2024), above global average of 88%
- TB-free Gram Panchayat certification: 46,118 gram panchayats certified TB-free in 2024
G. Treatment Monitoring & Outcomes
Standard NTEP outcome definitions:
| Outcome | Definition |
|---|---|
| Cured | Bacteriologically confirmed at start; smear/culture negative in last month + at least one earlier occasion |
| Treatment completed | Completed treatment without evidence of failure, but no confirmatory smear/culture results available |
| Treatment failed | Smear/culture positive at month 5 or later |
| Lost to follow-up | Treatment interrupted for ≥2 consecutive months |
Key References & Sources
- NTEP India TB Report 2024 (CTD, MoHFW) - primary NTEP guidelines document
- National Guidelines for Management of Drug-Resistant TB, 2024 (CTD) - updated DR-TB guidance including BPaLM
- PIB Press Release - India Speeding Towards TB Elimination, March 2026
- Park's Textbook of Preventive and Social Medicine - NTEP/RNTCP chapters
- WHO Global TB Report 2025
Note: Guidelines for extrapulmonary TB management under NTEP are currently being finalized (NTI consultation workshops, 2024-2025) and are expected to be published soon. The 4-month WHO regimen (for non-severe drug-sensitive TB) has not yet been formally adopted by NTEP as of mid-2026, pending local evidence.
This is a shared conversation. Sign in to Orris to start your own chat.